Fig. 4
From: Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
Effects of anti-TNF and MTX treatment on TL1A levels in rheumatoid arthritis. a Soluble TL1A was measured in serum samples from the AbCoN cohort [20] before or 14 weeks after treatment with TNF inhibitors. Subjects were classified by EULAR criteria into responders (good and moderate response, n = 34) and non-responders, n = 15. Significance for a change in TL1A was measured by Wilcoxon signed rank analysis. b Similar analysis was performed in a larger cohort (n = 100) of RA patients treated with golimumab, with serum TL1A levels shown at baseline compared to week 2 in all patients and week 14 in all patients, and grouped into responders (76) and non-responders (24) by EULAR criteria as in a. The right panel shows change in TL1A (14 weeks baseline) compared between responders and non-responders. The significance of the difference in ΔTL1A between responders and non-responders is given (Mann-Whitney non-parametric test). c Serum IL-6 measured in the same cohort of RA patients. Correlation with TL1A levels at baseline (left) and IL-6 levels at baseline and week 14 in all patients, and grouped into responders and non-responders by EULAR criteria as in b (right). d TL1A was measured in the serum before (baseline) or after 6 months of treatment with MTX monotherapy (17.5 mg/week) in 41 patients with early RA. Responsiveness was measured by EULAR criteria as described in the methods (23 good/moderate responders, 18 non-responders). e The change in TL1A (6 months baseline) was compared between responders and non-responders identified in d. The significance of the difference in ΔTL1A between responders and non-responders is given (Mann-Whitney non-parametric test)